Log in

Intellia Therapeutics Stock Forecast, Price & News

+3.52 (+9.82 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $39.38
50-Day Range
MA: $28.04
52-Week Range
Now: $39.38
Volume679,545 shs
Average Volume865,840 shs
Market Capitalization$2.33 billion
P/E RatioN/A
Dividend YieldN/A
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Intellia Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:NTLA



Sales & Book Value

Annual Sales$43.10 million
Book Value$5.52 per share


Net Income$-99,530,000.00
Net Margins-228.87%


Market Cap$2.33 billion
Next Earnings Date2/25/2021 (Estimated)
+3.52 (+9.82 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

How has Intellia Therapeutics' stock price been impacted by Coronavirus?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NTLA shares have increased by 209.6% and is now trading at $39.38.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Intellia Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Intellia Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Intellia Therapeutics?

Wall Street analysts have given Intellia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intellia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Intellia Therapeutics

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics Inc (NASDAQ:NTLA) posted its earnings results on Thursday, November, 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.54) by $0.07. The firm had revenue of $22.22 million for the quarter, compared to analyst estimates of $14.95 million. Intellia Therapeutics had a negative return on equity of 40.57% and a negative net margin of 228.87%. The business's quarterly revenue was up 109.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) earnings per share.
View Intellia Therapeutics' earnings history

What price target have analysts set for NTLA?

11 Wall Street analysts have issued 12-month price objectives for Intellia Therapeutics' stock. Their forecasts range from $20.00 to $57.50. On average, they anticipate Intellia Therapeutics' share price to reach $31.36 in the next twelve months. This suggests that the stock has a possible downside of 20.4%.
View analysts' price targets for Intellia Therapeutics

Who are some of Intellia Therapeutics' key competitors?

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:
  • Dr. John M. Leonard, Pres, CEO & Director (Age 63, Pay $903.79k)
  • Mr. Glenn G. Goddard, Exec. VP & CFO (Age 49, Pay $541.84k)
  • Dr. Andrew D. Schiermeier, Exec. VP & COO (Age 50, Pay $615.98k)
  • Dr. Laura Sepp-Lorenzino, Exec. VP & Chief Scientific Officer (Age 59, Pay $443.79k)
  • Mr. José E. Rivera, Exec. VP, Gen. Counsel & Company Sec. (Age 54, Pay $637.65k)
  • Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 47)
  • Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 34)
  • Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna, Founder & Member of Scientific Advisor Board (Age 56)
  • Dr. Derrick J. Rossi, Founder & Member of Scientific Advisor Board

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (19.42%), Nikko Asset Management Americas Inc. (10.32%), BlackRock Inc. (9.61%), State Street Corp (5.21%), Morgan Stanley (2.01%) and Point72 Asset Management L.P. (1.11%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, John M Leonard and Jose E Rivera.
View institutional ownership trends for Intellia Therapeutics

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nikko Asset Management Americas Inc., Jane Street Group LLC, Raymond James Financial Services Advisors Inc., Wells Fargo & Company MN, Platinum Investment Management Ltd., Cubist Systematic Strategies LLC, and Raymond James & Associates. Company insiders that have sold Intellia Therapeutics company stock in the last year include John M Leonard, and Jose E Rivera.
View insider buying and selling activity for Intellia Therapeutics

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., Engineers Gate Manager LP, AlphaCrest Capital Management LLC, Federated Hermes Inc., and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Intellia Therapeutics

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $39.38.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $2.33 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 270 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.